A multicenter randomized phase III study for newly diagnosed, maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide versus chemoradiotherapy alone: Japan Clinical Oncology Group study JCOG1703 (MACS study).
Ryuta Saito(Nagoya University), Yoshitaka Narita, Minako Sumi(Tokyo Metropolitan Geriatric Hospital), Junki Mizusawa(Japan Clinical Cancer Research Organization), Hiroshi Igaki(National Cancer Centre Japan), Fumiyuki Yamasaki(Hiroshima University), Ichiyo Shibahara(Kitasato University), Yuya Ishikawa(Japan Clinical Cancer Research Organization), Manabu Kinoshita(Asahikawa Medical University), Makoto Shibuya(Tokyo Medical University Hachioji Medical Center), Takashi Komori(Tokyo Metropolitan Neurological Hospital), Toshihiro Kumabe(Kitasato University), Atsushi Sasaki(Saitama Medical University), Yoshiki Arakawa(Kyoto University), Koichi Ichimura(Kyorin University), Fumiharu Ohka(Nagoya University), Masayuki Kanamori(Tohoku University), Keita Sasaki(Sumitomo Electric Industries (United States)), Yohei Mineharu(Kyoto University), Masahiro Nakano(Gifu University)
Cited by 0
Related Papers
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update
|Hepatology Research|2019|539
Apparent Diffusion Coefficient of Human Brain Tumors at MR Imaging
|Radiology|2005|505
Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial
|Journal of Thoracic and Cardiovascular Surgery|2019|496
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial
|Annals of Oncology|2019|333
Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis
|International Journal of Radiation Oncology*Biology*Physics|2001|188